Trial site
Minneapolis
Minneapolis, Minnesota 55455, United StatesNot linked to an institution yet
- 7running trials
- 3closed trials
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 22 trials
- Status
- Active, not recruiting6 trials
- Completed3 trials
- Recruiting1 trial
- Lead sponsor
- GlaxoSmithKline6 trials
- Tesaro, Inc.2 trials
- ViiV Healthcare2 trials
Running trials
Active, not recruiting
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504· Phase 2· GlaxoSmithKline· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Contact: Ajay Prakash (principal investigator)
Active, not recruiting
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520· Phase 3· ViiV Healthcare· Source
Active, not recruiting
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016· Phase 3· Tesaro, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error